130 related articles for article (PubMed ID: 12063682)
1. Doctor's dilemma: incorporating tumor markers into clinical decision-making.
Canil CM; Tannock IF
Semin Oncol; 2002 Jun; 29(3):286-93. PubMed ID: 12063682
[TBL] [Abstract][Full Text] [Related]
2. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers.
Sturgeon CM; Duffy MJ; Stenman UH; Lilja H; Brünner N; Chan DW; Babaian R; Bast RC; Dowell B; Esteva FJ; Haglund C; Harbeck N; Hayes DF; Holten-Andersen M; Klee GG; Lamerz R; Looijenga LH; Molina R; Nielsen HJ; Rittenhouse H; Semjonow A; Shih IeM; Sibley P; Sölétormos G; Stephan C; Sokoll L; Hoffman BR; Diamandis EP;
Clin Chem; 2008 Dec; 54(12):e11-79. PubMed ID: 19042984
[TBL] [Abstract][Full Text] [Related]
3. The use of serum tumor markers in the management of patients with malignancy.
Markman M
J Cancer Res Clin Oncol; 1993; 119(11):635-6. PubMed ID: 7688748
[No Abstract] [Full Text] [Related]
4. Testicular Cancer Biomarkers: A Role for Precision Medicine in Testicular Cancer.
Leão R; Ahmad AE; Hamilton RJ
Clin Genitourin Cancer; 2019 Feb; 17(1):e176-e183. PubMed ID: 30497810
[TBL] [Abstract][Full Text] [Related]
5. Serum tumor markers.
Perkins GL; Slater ED; Sanders GK; Prichard JG
Am Fam Physician; 2003 Sep; 68(6):1075-82. PubMed ID: 14524394
[TBL] [Abstract][Full Text] [Related]
6. Prostate-specific antigen in prostate cancer: a case study in the development of a tumor marker to monitor recurrence and assess response.
Small EJ; Roach M
Semin Oncol; 2002 Jun; 29(3):264-73. PubMed ID: 12063679
[TBL] [Abstract][Full Text] [Related]
7. Detection of vital germ cell tumor cells in short-term cell cultures of primary tumors and of retroperitoneal metastasis--clinical implications.
Otto T; Virchow S; Fuhrmann C; Steinberg F; Streffer C; Goepel M; Rübben H
Urol Res; 1997; 25(2):121-4. PubMed ID: 9144879
[TBL] [Abstract][Full Text] [Related]
8. Immunocytochemical evaluation of human prostatic carcinomas for carcinoembryonic antigen, nonspecific cross-reacting antigen, beta-chorionic gonadotrophin, and prostate-specific antigen.
Purnell DM; Heatfield BM; Trump BF
Cancer Res; 1984 Jan; 44(1):285-92. PubMed ID: 6197163
[TBL] [Abstract][Full Text] [Related]
9. MiR-371a-3p Serum Levels Are Increased in Recurrence of Testicular Germ Cell Tumor Patients.
Terbuch A; Adiprasito JB; Stiegelbauer V; Seles M; Klec C; Pichler GP; Resel M; Posch F; Lembeck AL; Stöger H; Szkandera J; Pummer K; Bauernhofer T; Hutterer GC; Gerger A; Stotz M; Pichler M
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30321995
[TBL] [Abstract][Full Text] [Related]
10. Carcinoembryonic antigen and carbohydrate antigen 19-9-producing adenocarcinoma of the prostate: report of an autopsy case.
Kodama S; Itoh H; Ide H; Kataoka H; Takehara T; Nagano M; Hamasuna R; Koono M; Osada Y
Urol Int; 1999; 63(3):193-7. PubMed ID: 10738193
[TBL] [Abstract][Full Text] [Related]
11. [Biological markers of cancer. Critical study].
Bellet D; Bidart JM
Presse Med; 1993 Apr; 22(14):680-6. PubMed ID: 8511115
[TBL] [Abstract][Full Text] [Related]
12. [Clinical usefulness of circulating tumor markers].
Ohkura H
Gan To Kagaku Ryoho; 2004 Jul; 31(7):1131-4. PubMed ID: 15272600
[TBL] [Abstract][Full Text] [Related]
13. Role of prostate specific antigen (PSA) and carcinoembryonic antigen (CEA) in screening for prostate and recurrent colon cancers in the elderly.
Vandenberg TA
Clin Biochem; 1993 Dec; 26(6):429-30. PubMed ID: 7510220
[No Abstract] [Full Text] [Related]
14. A simple computer program for calculating PSA recurrence in prostate cancer patients.
Liao Z; Datta MW
BMC Urol; 2004 Jun; 4():8. PubMed ID: 15207005
[TBL] [Abstract][Full Text] [Related]
15. Use of common seric tumor markers in patients with solid cancers.
Gara S; Boussen H; Ghanem A; Guemira F
Tunis Med; 2008 Jun; 86(6):579-83. PubMed ID: 19216452
[TBL] [Abstract][Full Text] [Related]
16. Tumor markers: value and limitations in the management of cancer patients.
Bates SE; Longo DL
Cancer Treat Rev; 1985 Sep; 12(3):163-207. PubMed ID: 2416441
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of five tumor markers (AFP, CEA, hCG, hPL and SP1) in monitoring therapy and follow-up of patients with testicular germ cell tumors.
Szymendera JJ; Zborzil J; Sikorowa L; Leńko J; Kamińska JA; Gadek A
Oncology; 1983; 40(1):1-10. PubMed ID: 6185897
[TBL] [Abstract][Full Text] [Related]
18. Predictive value of marker half-life in relapsed and nonrelapsed nonseminomatous germ cell testicular tumor patients undergoing chemotherapy.
Keskin S; Ekenel M; Başaran M; Bavbek S
Am J Clin Oncol; 2012 Aug; 35(4):369-72. PubMed ID: 22814307
[TBL] [Abstract][Full Text] [Related]
19. [Significance of current bio- and molecular-markers in urological cancers].
Shimazui T; Akaza H
Gan To Kagaku Ryoho; 2004 Jul; 31(7):1008-14. PubMed ID: 15272577
[TBL] [Abstract][Full Text] [Related]
20. Significance of human chorionic gonadotropin, alpha-fetoprotein, and pregnancy-specific beta-1-glycoprotein in the detection of tumor relapse and partial remission in 126 patients with nonseminomatous testicular germ cell tumors.
de Bruijn HW; Sleijfer DT; Schraffordt Koops H; Suurmeijer AJ; Marrink J; Ockhuizen T
Cancer; 1985 Feb; 55(4):829-35. PubMed ID: 2578303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
